Adaptive Biotechnologies
ADPT
214 hedge funds and large institutions have $3.46B invested in Adaptive Biotechnologies in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 76 increasing their positions, 69 reducing their positions, and 32 closing their positions.
442% more call options, than puts
Call options by funds: $6.41M | Put options by funds: $1.18M
10% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 69
3.75% more ownership
Funds ownership: 83.73% → 87.48% (+3.7%)
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
2% less funds holding
Funds holding: 219 → 214 (-5)
14% less capital invested
Capital invested by funds: $4B → $3.46B (-$542M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$56.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$35M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$34.7M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$34.7M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$25.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$31.5M |
| 2 |
CC
Casdin Capital
New York
|
-$13.5M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$13.2M |
| 4 |
BAMCO Inc
New York
|
-$12M |
| 5 |
DP
DDD Partners
Bellevue,
Washington
|
-$10.8M |
ADPT Hedge Fund Activity: Q4 2021 in Review
214 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2021, worth a combined $3.46B — down 14% from $4B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ADPT and 29 opened new positions — a net loss of 3 holders — while 69 trimmed existing stakes and 76 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $56.4M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $31.5M.
- 214 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2021, down from 219 in Q3 2021.
- Funds reported $3.46B of Adaptive Biotechnologies stock for Q4 2021, down 14% quarter-over-quarter.
- 29 funds opened new Adaptive Biotechnologies positions in Q4 2021 and 32 closed out, a net change of -3 holders.
- The largest Adaptive Biotechnologies buyer in Q4 2021 was T. Rowe Price Associates, an estimated $56.4M added.
- The largest Adaptive Biotechnologies seller in Q4 2021 was Gilder Gagnon Howe & Co, an estimated $31.5M sold.
Based on aggregated 13F filings for Q4 2021.